Odronextamab
Multispecific antibody
Evidence outlook
Approved: relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic... (EU)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also in development:Systemic Lupus Erythematosus · Phase 1 · investigational in the USDiffuse Large B-Cell Lymphoma · Phase 3 · investigational in the USB-Cell Non-Hodgkin Lymphoma · Phase 3 · investigational in the US
Also approved (2)
- Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.
- Monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
OLYMPIA-5 NCT06149286 · Follicular Lymphoma Registry: NCT06149286 | 3 | Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomide (Up to 35 days); Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomide (Up to 2 years); Severity of TEAEs for odronextamab in combination with lenalidomide (Up to 2 years); Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR) (Up to 5 years) 2031-04-30 | In progress: results expected 30 Apr 2031 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other CD20 x CD3 drugs
Epcoritamab, AZD5492, CND261, Plamotamab. Compare all 5 CD20 x CD3 drugs
4 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for B-Cell Non-Hodgkin Lymphoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Odronextamab: this drug | Phase 3 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 2 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD4512 | Phase 1/2 | Antibody–drug conjugate | CD22 | not yet graded | No reviewed efficacy summary in this indication | |
| CND261 | Phase 1(overall) | Biologic (subtype unspecified) | CD20 x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| JNJ-88998377 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Plamotamab | Phase 1(overall) | Multispecific antibody | CD20 x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| REGN5837 | Phase 1 | Multispecific antibody | CD22 x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3079 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Vispacabtagene Regedleucel | Discontinued | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Odronextamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (5)
February 2028 (1)
What to watch
March 2028 (1)
What to watch
April 2028 (1)
What to watch
May 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (4)
February 2029 (1)
What to watch
July 2029 (1)
What to watch
September 2029 (1)
What to watch
November 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent